Gonadotropin-releasing hormone antagonist Cetrorelix down-regulates proliferating cell nuclear antigen and epidermal growth factor expression and up-regulates apoptosis in association with enhanced poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human leiomyoma cells

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 2, 2005, Pages 884-892

  Chen, Wei ^a   Yoshida, Shigeki ^a   Ohara, Noriyuki ^a   Matsuo, Hiroya ^a   Morizane, Mayumi ^a   Maruo, Takeshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; CYCLINE; EPIDERMAL GROWTH FACTOR; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHENOL DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LEIOMYOMA; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ADULT; APOPTOSIS; BASE SEQUENCE; CELL SURVIVAL; DNA PRIMERS; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEIOMYOMA; POLY(ADP-RIBOSE) POLYMERASES; PREMENOPAUSE; PROLIFERATING CELL NUCLEAR ANTIGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

BOVINAE;

EID: 14044252941     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1591     Document Type: Article

References (50)

1. Vollenhoven BJ, Lawrence AS, Healy DL 1990 Uterine fibroids. Br J Obstet Gynaecol 97:285-298
2. Broekmans FJ 1996 GnRH agonists and uterine leiomyomas. Hum Reprod 3:3-25
3. Schally AV, Halmos G, Rekasi Z, Arencibia-Jimenez JM 2001 The actions of luteinizing hormone-releasing hormone agonists, antagonists, and cytotoxic analogues on the luteinizing hormone-releasing hormone receptors on the pituitary and tumors. Infertility Reprod Med Clin North Am 12:17-44
4. Kettel LM, Rivier J, Murphy AA, Vale W, Morales AJ, Yen SSC 1993 Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril 60:642-646
5. Gonzalez-Barcena D, Alvarez RB, Ochoa EP, Cornejo IC, Comaru-Schally AM, Schally AV, Engel J, Reismann T, Riethmüller-Winzen H 1997 Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 12:2028-2035
6. Felberbaum RE, Germer U, Ludwig M, Riethmüller-Winzen H, Heise S, Buttge I, Bauer O, Reissmann T, Engel J, Diedrich K 1998 Treatment of uterine fibroids with a slow-release formulation of the gonadotropin releasing hormone antagonist Cetrorelix. Hum Reprod 13:1660-1668
7. Felberbaum RE, Küpker W, Krapp M, Gehl B, Ludwig M, Diedrich K 2001 Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotropin-releasing hormone antagonist (Cetrorelix). Reprod Biomed Online 3:14-18
8. Reissmann T, Schally AV, Bouchard P, Riethmüller H, Engel J 2000 The LHRH antagonist Cetrorelix: a review. Hum Reprod Update 6:322-331
9. Horvath JE, Toller GL, Schally AV, Bajo A-M, Groot K 2004 Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Proc Natl Acad Sci USA 101:4996-5001
10. Wizniter A, Marbach M, Hazum E, Insler V, Sharoni Y, Levy J 1988 Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem Biophys Res Commun 152:1326-1331
11. Chegini N, Rong H, Dou Q, Kipersztok S, Williams RS 1996 Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. J Clin Endocrinol Metab 81:3215-3221
12. Kobayashi Y, Zhai YL, Iinuma M, Horiuchi A, Nikaido T, Fujii S 1997 Effects of a GnRH analogue on human smooth muscle cells cultured from normal myometrial and from uterine leiomyomal tissues. Mol Hum Reprod 3:91-99
13. Wang Y, Matsuo H, Kurachi O, Maruo T 2002 Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. Eur J Endocrinol 146:447-456
14. Chatzaki E, Bax CMR, Eidne KA, Anderson L, Grudzinskas G, Gallagher CJ 1996 The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Cancer Res 56:2059-2065
15. Kottler M-L, Starzec A, Carre M-C, Lagarde J-P, Martin A, Counis R 1997 The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. Int J Cancer 71:595-599
16. Lamharzi N, Halmos G, Armatis P, Schally AV 1998 Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int J Oncol 12:671-675
17. Lamharzi N, Halmos G, Jungwirth A, Schally AV 1998 Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol 13:429-435
18. 6] luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 12:489-498
19. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, Motta M 1999 The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 140:5250-5256
20. Arencibia JM, Schally AV 2000 Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line. Int J Oncol 16:1009-1013
21. Kang SK, Cheng KW, Nathwani PS, Choi K-C, Leung PCK 2000 Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth. Endocrine 13:297-304
22. Noci I, Coronnello M, Boni P, Borrani E, Giachi M, Chieffi O, Marchionni M, Paglierani M, Buccoliero AM, Cherubini A, Arcangeli A, Mini E, Taddei G 2000 Inhibitory effect of luteinizing hormone-releasing hormone analogues on human endometrial cancer in vitro. Cancer Lett 150:71-78
23. Gründlker C, Günthert AR, Millar RP, Emons G 2002 Expression of gonadotropin-releasing hormone II (GnRH-III receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 87:1427-1430
24. Völker P, Gründker C, Schmidt O, Schulz K-D, Emons G 2002 Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 186:171-179
25. Gründlker C, Günthert AR, Westphalen S, Emons G 2002 Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 146:1-14
26. Emons G, Gründlker C, Günthert AR, Westphalen S, Kavanagh J, Verschraegen C 2003 GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 10:291-299
27. Gründlker C, Emons G 2003 Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol 1:65-71
28. Maruo T, Ohara N, Wang J, Matsuo H 2004 Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 10:207-220
29. Yeh J, Rein M, Nowak R 1991 Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata. Fertil Steril 56:997-1000
30. Harrison-Woolrych ML, Charnock-Jones DS, Smith SK 1994 Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab 78:1179-1184
31. Shimomura Y, Matsuo H, Samoto T, Maruo T 1998 Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 83:2192-2198
32. Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M, Limonta P 1996 Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81:3930-3937
33. Szepesházi K, Halmos G, Schallý AV, Arencibia JM, Groot K, Vadillo-Buenfil M, Rodriguez-Martin E 1999 Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. J Cancer Res Clin Oncol 125:444-452
34. Gründlker C, Völker P, Schulz K-D, Emons G 2000 Luteinizing hormone-releasing hormone agonist Triptorelin and antagonist Cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecol Oncol 78: 194-202
35. Chatzistamou I, Schally AV, Szepeshazi K, Groot K, Hebert F, Arencibia JM 2001 Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. Cancer Lett 171:37-45
36. 1-mediated activation of phosphotyrosine phosphatase. Endocrinology 142:2369-2380
37. Weiss JM, Oltmanns K, Gurke EM, Polack S, Eick F, Felberbaum R, Diedrich K, Ortmann O 2001 Actions of gonadotropin releasing hormone antagonists on steroidogenesis in human granulosa lutein cells. Eur J Endocrinol 144:677-685
38. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
39. Shacham S, Cheifetz MN, Levy H, Ashkenazi IE, Becker OM, Seger R, Naor Z 1999 Mechanism of GnRH receptor signaling: from the membrane to the nucleus. Ann Endocrinol (Paris) 60:79-88
40. Imai A, Takagi H, Horibe S, Fuseya T, Tamaya T 1996 Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. J Clin Endocrinol Metab 81:3249-3253
41. Imai A, Takagi H, Furui T, Horibe S, Fuseya T, Tamaya T 1996 Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane. Cancer 77:132-137
42. Pinski J, Reile H, Halmos G, Groot K, Schally AV 1994 Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer 59:51-55
43. Pagnini U, Florio S, Crispino L, Pagnini G, Colangelo D, Rocco D, Pacilio C, Pacilio M, Macaluso M, Giordano A 2002 Direct effect of a gonadotropin-releasing hormone agonist on the growth of canine mammary tumour cells. J Cell Biochem 85:470-481
44. Emons G, Muller V, Oltmann O, Schulz KD 1998 Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 65:199-206
45. Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT 1992 Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res 52:2538-2544
46. Bifulco G, Miele C, Pellicano M, Trencia A, Ferraioli M, Paturzo F, Tommaselli GA, Beguinot F, Nappi C 2004 Molecular mechanisms involved in GnRH analogue-related apoptosis for uterine leiomyomas. Mol Hum Reprod 10:43-48
47. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, Smulson M 1999 Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspases 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274:22932-22940
48. Chiarugi A 2002 Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol Sci 23:122-129
49. Soldani C, Scovassi AI 2002 Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7:321-328
50. Bouchard VJ, Rouleau M, Poirier GG 2003 PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 31:446-454